On June 10, AKeso (09926.HK) fell 3.35% in regular trading, trading at HKD 85.9/share with trading volume of HKD 371 million. The stock is now approaching its 52-week low of HKD 82.15, having declined over 25% from its post-ASCO high on June 1.

The decline extends the persistent pullback following the company's presentation of HARMONi-6 OS-positive results at the ASCO Plenary Session on June 1, where its core drug ivonescimab demonstrated a hazard ratio of 0.66, reducing death risk by 34% in first-line squamous NSCLC. Despite the landmark data — making it the first Chinese-originated drug to present Phase III results at ASCO's highest-profile session in 61 years — event-driven funds have been systematically taking profits since the catalyst was fully priced in. Reports of potential US restrictions on investment in China's biotech sector have further weighed on sentiment. The stock has now lost over HKD 10 billion in market capitalization since the data release, even as multiple brokerages including BOCOM International and CITIC Securities maintain buy ratings with targets above HKD 175.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)